ADMA Biologics (NASDAQ: ADMA) is a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. ADMA's targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. ADMA's product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with infectious diseases.
ADMA also operates ADMA BioCenters, an FDA-licensed, GHA-certified source plasma collection facility which provides a portion of blood plasma for the manufacture of its lead product candidate RI-002.
BetterDoctor is a digital health marketplace startup revolutionizing the way consumers search for and discover highly qualified doctors. With 1 billion medical appointments occurring annually, 250 thousand medical practices, and hundreds of insurance plans in the US healthcare system, the process of finding the right doctor and booking medical appointments is very inefficient and lacks transparency. By aggregating disparate sets of healthcare and consumer data, BetterDoctor is creating an analytics engine that verifies the quality of the doctors and powers BetterDoctor's mobile and web apps, which provide consumers personalized recommendations of the best doctors in a matter of minutes and with just a handful of clicks, eliminating the need to spend hours manually searching through online directories and verifying availability one by one.
Flexible Stenting Solutions (FSS) is a New Jersey based private company developing and commercializing flexible, strong and durable stents that are built on a proprietary FlexStent® technology platform and a unique delivery system. The Company’s broad product platform includes third-generation flexible peripheral arterial, venous, neurovascular and biliary stents. The FSS stents offer advantages over currently available stents including: greater stent flexibility, improved scaffolding and radial strength, and greater fracture and kink resistance. The company’s reconstrainable stent and delivery system offers a unique game changing technology to the peripheral stent market.
Flexible Stenting Solutions was acquired by Cordis Corporation, a division of Johnson & Johnson, on March 12, 2013.
HyperMed is developing hyperspectral imaging for medical applications. The technology, originally developed for military surveillance, provides an advanced form of spectroscopy that provides a two-dimensional tissue oxygenation map. The company has developed a new product using the same breakthrough imaging technology as used in its OxyVu™-1 system. HyperMed’s new product, called HyperView™, is FDA 510(k) cleared. HyperView is designed to deliver the same diagnostic information in a smaller, more portable configuration. Multiple published studies have demonstrated the clinical utility of OxyVu for the diagnostic assessment of wound healing, diabetic foot ulcers, and amputation planning. technology has been in service since 2006 and has been shown in published clinical research to effectively assess oxyhemoglobin, deoxyhemoglobin and oxyhemoglobin saturation in superficial tissue for a number of key healthcare applications.The market opportunity for the clinical diagnostic applications for hyperspectral imaging represent a multi-billion market.
i2Dx is developing a multimodal, cloud-based diagnostic platform for the assessment of neurological disorders. The platform will provide quantitative digital assessments of a number of biomarkers that are indicative of brain health with the goal of providing a personalized, longitudinal brain record for healthy individuals and patients.
JHL Biotech (TWEM: 6540) was founded in 2012 with a vision of making biopharmaceuticals affordable and accessible to all patients through manufacturing innovation. To achieve this vision, JHL will provide world-class process development and manufacturing services in Asia to companies developing and commercializing high-quality, affordable biologic medicines. JHL is leveraging the latest process and engineering technologies to reduce the complexity and cost of mammalian cell culture manufacturing. These technologies will be incorporated into world-class biologics API manufacturing facilities in Asia that comply with US, EU and ICH cGMP regulations and guidelines.
Led by an experienced team of Genentech and Amgen veterans, and funded by top-tier venture capital firms including Kleiner Perkins Caufield & Byers (KPCB), Sequoia Capital, Biomark Capital and CDIB, JHL is uniquely positioned to deliver manufacturing solutions to its worldwide partners.
Juno Therapeutics (NASDAQ: JUNO) is focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human T cells as therapeutics will drive one of the next important phases in medicine, the company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno Therapeutics has shown compelling evidence of tumor shrinkage in clinical trials using multiple cell-based product candidates to address refractory B-cell lymphomas and leukemias. Longer term, the company aims to develop its cell-based platform to include additional product candidates to address a broad range of cancers and human diseases.
On January 22, 2018, Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics (NASDAQ:JUNO) announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno.
Opus Bio (formerly Lentigen Corporation) is a diversified biologics company focused on the development and commercialization of breakthrough treatments for human disease. Lentiviral vectors (LV), the company's technology platform, are widely recognized by the scientific community as the most efficient method for delivery of genetic sequence information into cells to reprogram their function. The ability to efficiently and stably reprogram mammalian cells has numerous uses in biotechnology and biomedicine, including drug discovery, target validation, biologics manufacturing and cellular therapies.
Opus's most advanced clinical candidate is a T-cell chimeric antigen receptor cellular therapy targeting CD22 for hematological malignancies. In December 2014, the company has entered into an agreement to license the CD22 program to Juno Therapeutics (NASDAQ:JUNO). Phase I clinical study for this compound is enrolling and treating patients. Opus Bio has also secured the rights to other proprietary antigens that combined with its lentiviral vector may have broad applicability across epithelial cancers, including colon, small-cell lung, ovarian, breast cancer, stomach, and esophageal, among others.
Strand Life Sciences provides bioinformatics solutions with advanced visualization, predictive systems modeling, data integration, and scientific context management components to transform raw data into actionable insights. The company employs 200 people, mostly in Bangalore, India, and services both the research and clinical markets.
Strand enjoys three advantages over the competition globally: superior software analytics, superior curation of gene variants, and a major cost advantage for DNA test interpretation. When combined, Strand is finding a rapidly growing demand for its StrandOmics software platform, which hospitals and service providers can use to service their patients and healthcare clients. With every sequence and gene test, the company’s cloud database gets more valuable with related metadata, which can be used to improve future analytics, thereby creating an additional demand for StrandOmics.
Strand has developed the most advanced software for analyzing DNA sequences. Today, 1,400 research institutions worldwide use Strand’s software under the product names GeneSpring (marketed by Agilent) and Avadis (marketed by Strand). The company reached profitability in 2007, and in early 2013, the company began to service the clinical market in India. It opened its own DNA sequence and gene panel wet lab in Bangalore, India, and in December, the company opened a lab which it operates in the 1,400-bed Mazumdar-Shaw Cancer Center in Bangalore. By the end of 2013, Strand was servicing the gene testing and DNA sequence analysis needs of over 100 hospitals in India, and in 2014 it has begun to expand into the US market.
WaveTec is committed to developing and providing innovative wavefront measurement technology for cataract surgeons. WaveTec's revolutionary ORA System® provides real-time, intraoperative refractive information to ophthalmologists worldwide, allowing them to deliver the best possible vision for their cataract patients.
On August 27, 2014 Alcon, the global leader in eye care and the second largest division of Novartis Group, announced that the company has entered into an agreement to acquire WaveTec Vision.
WhiteGlove’s Complete Health Solution™ provides a comprehensive suite of technology-enabled health and wellness services – including biometrics, wellness coaching, acute care, telemedicine, chronic care, and on-site services – delivered by our clinical team. This service, combined with powerful web-based portals for the member and employer provide the capabilites required to monitor and improve health and wellness. Because WhiteGlove's solution leverages a single view of the patient and is able to clinically intervene when care is needed, we eliminate the complexities and flaws of current wellness and population health management strategies.
Founded on the idea, "Think Differently About Healthcare", and delivering an exceptional healthcare experience, WhiteGlove empowers employees and dependents to better manage their own health and wellnesss.